The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Investors await the Fed's latest decision on monetary policy, set to be released on Wednesday stateside. The U.S. central bank is widely expected to cut rates by 25 basis...Asia Marketsread more
Large banking institutions face the risk of failure if interest rates in Europe continue to stay negative, warns the global chief economist of the Economist Intelligence Unit.Banksread more
Live the high life with a night's stay at Highclere Castle, the iconic stately home made famous by Downton Abbey.Spendread more
The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
The U.S. Air Force's top general says he hasn't received direction to send additional bombers to the Middle East after what is believed to be Iranian attacks on Saudi Arabian...Defenseread more
Facebook has partnered with Ray-Ban maker Luxottica to develop augmented-reality glasses code-named 'Orion', people familiar with the matter told CNBC.Technologyread more
Government intervention isn't the answer to keeping drug prices in line, Allergan CEO Brent Saunders said Thursday.
The pharmaceutical company, which makes products such as Botox, recently pledged to limit annual increases on prescription drugs — and Saunders believes others can do the same.
"This isn't something the government can solve, because it isn't a bright line — it's a facts and circumstance test. And so I'd rather industry self-police, which is what Allergan is doing. We're making a very bold commitment to say we're not going to engage in this practice," he said in an interview with CNBC's "Closing Bell."
On Tuesday, Saunders announced the company would raise prices no more than once a year and would keep price increases to no more than low-to-mid-single-digit percentages, slightly above the current annual rate of inflation.
Instead of getting pushback from the drug industry, Allergan has gotten positive feedback, he said.
"I've heard from numerous employees all over the world. ... I've heard from physicians, I've heard from shareholders, I've heard from peers, I've heard from smaller company CEOs, all very encouraging feedback so far."
The pharma industry has been under a microscope since Mylan hiked the price of its EpiPen to $600. The outrage has caught fire politically, and Democratic presidential nominee Hillary Clinton has said if elected, she would create an oversight panel to monitor price increases and impose penalties for unjustified hikes.
However, Saunders said it isn't easy to determine who is an outlier company. Instead, it comes down to the facts and circumstances surrounding the price increase.
"If you're taking old drugs and you're building an entire business model over price increases versus investing in innovation and looking for cures and treatments for unmet medical needs, then you are probably moving into an egregious pricing condition."
Saunders said his comments weren't meant to be a criticism of any particular company. However, when asked if Mylan could lower the price of the EpiPen, he responded, "If they wanted to cut the price of the drug, they could do it. We can do it, they can do it, anybody can do it."